Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China

Purpose: This study aimed to compare the clinical outcomes of camrelizumab in hepatitis B virus-related hepatocellular carcinoma (HBV–HCC) patients and non-HBV, non-HCV hepatocellular carcinoma (NBNC–HCC) patients in China. Materials and methods: A total of 54 patients with hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haonan, Qin, Xiaobing, Xu, Zhiyuan, Wu, Meng, Lu, Tong, Zhou, Shuang, Yao, Nan, Liu, Suya, Shao, Yong, Han, Zhengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500546/
https://www.ncbi.nlm.nih.gov/pubmed/36160021
http://dx.doi.org/10.3389/fgene.2022.1000448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500546/
https://www.ncbi.nlm.nih.gov/pubmed/36160021
http://dx.doi.org/10.3389/fgene.2022.1000448

Ejemplares similares